A phase II trial of amonafide in patients with endometrial cancer - A gynecologic oncology group study

被引：4

作者：

Asbury, R

Blessing, JA

Reid, GC

McGuire, WP

机构：

[1] Univ Rochester, Sch Med, Dept Med Oncol, Rochester, NY USA

[2] Roswell Pk Canc Inst, Gynecol Oncol Grp, Buffalo, NY USA

[3] Riverside Methodist Hosp, Dept Gynecol Oncol, Columbus, OH 43214 USA

[4] Emory Univ, Dept Med, Atlanta, GA 30322 USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1998年 / 21卷 / 04期

关键词：

amonafide; endometrial cancer;

D O I：

10.1097/00000421-199808000-00018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-nine evaluable patients with endometrial cancer were treated with amonafide 300 mg/m(2) for 5 consecutive days every 3 weeks. Two partial responses (8%) were seen. Hematologic toxicity was severe or life-threatening in 13 patients occurring as follows: leukopenia in 13 patients (45%); thrombocytopenia in 10 patients (34%); granulocytopenia in 13 patients (45%); and anemia in four patients (14%). In view of the low response rate and high toxicity, this dose schedule of amonafide does not warrant further investigation in endometrial cancer.

引用

页码：406 / 407

页数：2